欢迎浏览论文快速发表网,我们为你提供专业的论文发表咨询和论文写作指导。 [设为首页] [加入收藏]
社科类论文 科技类论文 医学类论文 管理类论文 教育类论文 农林类论文 新闻类论文 建筑类论文 文艺类论文 法学类论文
论文范文

Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury
时间:2018-11-14 21:05   来源:未知   作者:admin   点击:
       Abstract:The peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist rosiglitazone inhibits NF-κB expression and endogenous neural stem cell differentiation into neurons and reduces the inflammatory cascade after spinal cord injury (SCI). The aim of this study was to explore the mechanisms underlying rosiglitazone-mediated neuroprotective effects and regulation of the balance between the inflammatory cascade and generation of endogenous spinal cord neurons by using a spinal cord-derived neural stem cell culture system as well as SD rat SCI model. Activation of PPAR-γ could promote neural stem cell proliferation and inhibit PKA expression and neuronal formation in vitro. In the SD rat SCI model, the rosiglitazone + forskolin group showed better locomotor recovery compared to the rosiglitazone and forskolin groups. MAP2 expression was higher in the rosiglitazone + forskolin group than in the rosiglitazone group, NF-κB expression was lower in the rosiglitazone + forskolin group than in the forskolin group, and NeuN expression was higher in the rosiglitazone + forskolin group than in the forskolin group. PPAR-γ activation likely inhibits NF-κB, thereby reducing the inflammatory cascade, and PKA activation likely promotes neuronal cell regeneration.
1. Introduction
      Acute spinal cord injuries (SCI) are severe and often permanent and can prove expensive for patients and the community. SCI is the highest cause of death in young people (15–29 years of age) [1]. There are currently no treatments which have a proven positive effect on neurological outcome [2, 3], following acute SCI. Spinal cord injury results in primary initial damage and subsequent secondary damage [4]. The secondary damage due to early inflammatory responses after spinal cord injury is the main cause for neurological defects and exacerbates the initial degree of injury [5] and the secondary damage usually caused by ischemia, cellular and tissue edema, and oxidative damage [6].
      In our previous research, we found that activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) could promote locomotor recovery after spinal cord injury [7]. PPAR-γ is a PPAR nuclear receptor subtype. There are two types of PPAR-γ ligands: natural ligands such as fatty acids and eicosanoid derivatives [8] and synthetic ligands such as thiazolidinediones ketones (thiazolidinedione, TZD), of which rosiglitazone (rosiglitazone) and pioglitazone (pioglitazone) are used in clinical medicine as a treatment for type 2 diabetes [9]. Rosiglitazone is part of the thiazolidinediones nuclear hormone receptor superfamily and is known for its anti-inflammatory actions via the activation of PPAR-γ. Rosiglitazone attenuates the expression of proinflammatory genes and cytokine production by regulating ligand activation of transcription factors [10, 11]. And rosiglitazone has neuroprotective effects in neurodegenerative diseases and spinal cord injury [12, 13]. We previously reported that application of the PPAR-γ agonist rosiglitazone could significantly inhibit activation of the key inflammatory cascade target nuclear transcription factor kappa B (nuclear factor kappa B; NF-κB) after spinal cord injury [7].
       NF-κB is extracted from B lymphocytes and is named because of its binding to the immunoglobulin chain gene enhancer sequence-specific κB [14]. The NF-κB family of transcription factors has an essential role in inflammation and innate immunity. The active form of NF-κB is a dimer, typically a P50 / P65 heterodimer, and is the main component of the NF-κB family involved in gene transcription [15]. Members of the NF-κB family participate in many physiological processes, including regulation of the immune response, stimulation of immune cell maturation, and the production and survival of essential transcription factors for B cells [15].
      In our preliminary research, we found that PPAR-γ could inhibit NF-κB activation and promote proliferation and inhibit neural differentiation of endogenous neural stem cells [7]. The NF-κB and PPAR-γ signaling pathways are closely related; PPAR-γ activation along with inhibition of the NF-κB-cytokine cascade could protect against dextran sulfate sodium-induced colitis in mice [16]. PPAR-γ could also attenuate inflammation via NF-κB inhibition in lipopolysaccharide-induced peritonitis [17]. In addition to functions in glucose and lipid metabolism and cell proliferation and differentiation, PPAR-γ can also alleviate the acute and chronic inflammatory response after nerve injury and ameliorate neuronal apoptosis and ischemic brain injury by suppressing NF-κB-driven p22phox transcription [18].


推荐期刊 论文范文 学术会议资讯 论文写作 发表流程 期刊征稿 常见问题 网站通告
论文快速发表网(www.k-fabiao.com)版权所有,专业学术期刊论文发表网站
代理杂志社征稿、杂志投稿、省级期刊、国家级期刊、SCI/EI期刊、学术论文发表,中国学术期刊网全文收录